City National Bank of Florida MSD Buys Shares of 683 Thermo Fisher Scientific Inc. (NYSE:TMO)

City National Bank of Florida MSD purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 683 shares of the medical research company's stock, valued at approximately $355,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Wedge Capital Management L L P NC lifted its stake in Thermo Fisher Scientific by 4.1% in the fourth quarter. Wedge Capital Management L L P NC now owns 706 shares of the medical research company's stock valued at $367,000 after acquiring an additional 28 shares during the last quarter. LaFleur & Godfrey LLC lifted its stake in Thermo Fisher Scientific by 9.1% in the fourth quarter. LaFleur & Godfrey LLC now owns 29,767 shares of the medical research company's stock valued at $15,486,000 after acquiring an additional 2,488 shares during the last quarter. Koshinski Asset Management Inc. lifted its stake in Thermo Fisher Scientific by 2.0% in the fourth quarter. Koshinski Asset Management Inc. now owns 2,700 shares of the medical research company's stock valued at $1,405,000 after acquiring an additional 54 shares during the last quarter. Pure Financial Advisors LLC lifted its stake in Thermo Fisher Scientific by 7.0% in the fourth quarter. Pure Financial Advisors LLC now owns 1,117 shares of the medical research company's stock valued at $581,000 after acquiring an additional 73 shares during the last quarter. Finally, Alpha Cubed Investments LLC lifted its stake in Thermo Fisher Scientific by 6.3% in the fourth quarter. Alpha Cubed Investments LLC now owns 623 shares of the medical research company's stock valued at $324,000 after acquiring an additional 37 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock traded down $6.95 on Friday, hitting $393.53. 2,318,052 shares of the stock were exchanged, compared to its average volume of 1,869,410. The firm's 50 day moving average is $442.54 and its two-hundred day moving average is $504.86. The firm has a market capitalization of $148.56 billion, a PE ratio of 23.81, a P/E/G ratio of 2.99 and a beta of 0.82. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a one year low of $390.50 and a one year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. The firm had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The company's revenue was up .2% compared to the same quarter last year. During the same quarter last year, the firm posted $5.11 EPS. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 annualized dividend and a dividend yield of 0.44%. Thermo Fisher Scientific's dividend payout ratio is 10.09%.

Analyst Ratings Changes

A number of brokerages have recently weighed in on TMO. The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the stock a "buy" rating in a research note on Wednesday, April 23rd. Evercore ISI reduced their price objective on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. UBS Group reduced their price objective on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating for the company in a research note on Thursday, April 24th. Barclays reduced their price objective on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a research note on Thursday, April 10th. Finally, Robert W. Baird reduced their price objective on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Four investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $607.43.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president now owns 23,167 shares of the company's stock, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of the business's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the sale, the senior vice president now directly owns 10,816 shares of the company's stock, valued at $5,759,736.32. This represents a 25.87% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 14,075 shares of company stock worth $7,305,942 over the last ninety days. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.